Depreciation and amortization 865 724
Stock option expense 8,040 4,837
EBITDASO $ 26,637 $ 19,661
EBITDASO earnings per share (1):
Basic $ 1.26 $ 0.85
Diluted $ 1.19 $ 0.79
(1) Calculated by dividing pro forma net income from above by weighted average shares outstanding, as reported below.
United Therapeutics will host a one hour teleconference on Thursday, November 1, 2007, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-800-603-1777, with international callers dialing 1-706-679-8129. A rebroadcast of the teleconference will be available for one week following the teleconference by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291, and using access code 20811764.
This teleconference is also being web cast and can be accessed via United Therapeutics' website at http://ir.unither.com/eventdetail.cfm?eventid=45704.
About United Therapeutics
United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.
Non-GAAP Financial Information
This press release contains certain financial measures that do not comply with GAAP, which measures supplement our financial results prepared in accordance with GAAP.
We believe that the presentation of pro forma net income, a non-GAAP
measure, is meaningful to investors, when used in conjunction with United
Therapeutics' financial statements, because it aids them in comparing our
financial results for such periods taking into account the effect
|SOURCE United Therapeutics Corporation|
Copyright©2007 PR Newswire.
All rights reserved